MX2007010608A - Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma. - Google Patents
Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma.Info
- Publication number
- MX2007010608A MX2007010608A MX2007010608A MX2007010608A MX2007010608A MX 2007010608 A MX2007010608 A MX 2007010608A MX 2007010608 A MX2007010608 A MX 2007010608A MX 2007010608 A MX2007010608 A MX 2007010608A MX 2007010608 A MX2007010608 A MX 2007010608A
- Authority
- MX
- Mexico
- Prior art keywords
- glaucoma
- related protein
- rnai
- treatment
- mediated inhibition
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 3
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 title abstract 2
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 108091030071 RNAI Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66055605P | 2005-03-11 | 2005-03-11 | |
| US68863305P | 2005-06-08 | 2005-06-08 | |
| PCT/US2006/009000 WO2006099353A1 (en) | 2005-03-11 | 2006-03-10 | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007010608A true MX2007010608A (es) | 2007-10-19 |
Family
ID=36649793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007010608A MX2007010608A (es) | 2005-03-11 | 2006-03-10 | Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma. |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US7947660B2 (https=) |
| EP (1) | EP1856259A1 (https=) |
| JP (2) | JP2008533050A (https=) |
| KR (1) | KR20080018858A (https=) |
| AU (1) | AU2006223131A1 (https=) |
| BR (1) | BRPI0609206A2 (https=) |
| CA (1) | CA2598234A1 (https=) |
| MX (1) | MX2007010608A (https=) |
| WO (1) | WO2006099353A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171010T8 (hr) | 2004-08-23 | 2017-11-03 | Sylentis S.A.U. | Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk |
| KR20080018858A (ko) * | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해 |
| GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| RU2010117178A (ru) * | 2007-10-01 | 2011-11-10 | Алькон Рисерч, Лтд. (Us) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний |
| US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| AR069328A1 (es) | 2007-11-15 | 2010-01-13 | Alcon Mfg Ltd | Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad |
| TW200932274A (en) | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
| US20120271272A1 (en) | 2010-10-15 | 2012-10-25 | Iscience Interventional Corporation | Device for ocular access |
| WO2012161677A1 (en) | 2011-05-20 | 2012-11-29 | Alcon Research, Ltd. | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY |
| US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| SG11201501385UA (en) | 2012-09-05 | 2015-03-30 | Sylentis Sau | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2916827B1 (en) | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
| EP3003454B1 (en) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Apparatus for drug delivery using multiple reservoirs |
| US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| RU2710491C2 (ru) | 2014-06-20 | 2019-12-26 | Клиасайд Байомедикал, Инк. | Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань |
| USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
| WO2017139375A1 (en) | 2016-02-10 | 2017-08-17 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
| CA3062845A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
| EP3496680B1 (en) | 2016-08-12 | 2024-10-02 | Clearside Biomedical, Inc. | Device for adjusting the insertion depth of a needle for medicament delivery |
| WO2018204515A1 (en) | 2017-05-02 | 2018-11-08 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
| JP7641902B2 (ja) * | 2019-01-29 | 2025-03-07 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | 緑内障の新規治療法 |
| US20230201371A1 (en) * | 2020-03-19 | 2023-06-29 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
| EP4536197A1 (en) | 2022-06-07 | 2025-04-16 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP2314700A1 (en) * | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20080166356A9 (en) * | 1999-09-13 | 2008-07-10 | Peter Bodine | Pharmaceutical compositions and methods of using secreted frizzled related protein |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| WO2005019453A2 (en) * | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1974738A3 (en) * | 2000-02-29 | 2008-12-17 | Alcon, Inc. | Diagnostics and therapeutics for glaucoma |
| DE10012340A1 (de) | 2000-03-14 | 2001-09-20 | Merck Patent Gmbh | Verfahren zur Baeyer-Villiger-Oxidation organischer Carbonylverbindungen |
| EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| PT1309726E (pt) * | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| WO2003049773A1 (en) * | 2001-12-11 | 2003-06-19 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
| AU2003237143A1 (en) | 2002-05-03 | 2003-11-17 | Alcon, Inc. | Diagnosis and treatment of glaucoma |
| AU2003225233A1 (en) * | 2002-05-03 | 2003-11-17 | Alcon, Inc. | Diagnosis and treatment of glaucoma and methods for discovering new glaucoma therapeutic agents based on the wnt/ca2+ signaling pathway |
| WO2003093441A2 (en) * | 2002-05-03 | 2003-11-13 | Duke University | A method of regulating gene expression |
| WO2004014933A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| US20040198967A1 (en) | 2002-09-04 | 2004-10-07 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth | Compositions and methods for tissue specific or inducible inhibition of gene expression |
| US20040072769A1 (en) * | 2002-09-16 | 2004-04-15 | Yin James Qinwei | Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20040175732A1 (en) * | 2002-11-15 | 2004-09-09 | Rana Tariq M. | Identification of micrornas and their targets |
| US20040191818A1 (en) * | 2003-02-26 | 2004-09-30 | O'toole Margot Mary | Compositions and methods for diagnosing and treating autoimmune diseases |
| WO2005090606A2 (en) * | 2004-01-23 | 2005-09-29 | Dharmacon, Inc. | Identification of toxic nucleotide sequences |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| KR101147147B1 (ko) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| TWI401316B (zh) | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用 |
| TWI386225B (zh) | 2004-12-23 | 2013-02-21 | Alcon Inc | 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術 |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| KR20080018858A (ko) * | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해 |
-
2006
- 2006-03-10 KR KR1020077021405A patent/KR20080018858A/ko not_active Ceased
- 2006-03-10 WO PCT/US2006/009000 patent/WO2006099353A1/en not_active Ceased
- 2006-03-10 EP EP06738105A patent/EP1856259A1/en not_active Ceased
- 2006-03-10 MX MX2007010608A patent/MX2007010608A/es active IP Right Grant
- 2006-03-10 AU AU2006223131A patent/AU2006223131A1/en not_active Abandoned
- 2006-03-10 CA CA002598234A patent/CA2598234A1/en not_active Abandoned
- 2006-03-10 US US11/373,376 patent/US7947660B2/en active Active
- 2006-03-10 JP JP2008501049A patent/JP2008533050A/ja not_active Withdrawn
- 2006-03-10 BR BRPI0609206-3A patent/BRPI0609206A2/pt not_active Application Discontinuation
-
2011
- 2011-04-12 US US13/084,944 patent/US8173617B2/en not_active Expired - Lifetime
-
2012
- 2012-03-26 US US13/429,913 patent/US9040494B2/en active Active
- 2012-07-10 JP JP2012154550A patent/JP2012193197A/ja active Pending
-
2015
- 2015-04-21 US US14/692,402 patent/US9550994B2/en not_active Expired - Lifetime
-
2016
- 2016-11-30 US US15/364,992 patent/US20170073681A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170073681A1 (en) | 2017-03-16 |
| WO2006099353A1 (en) | 2006-09-21 |
| US8173617B2 (en) | 2012-05-08 |
| US20150307882A1 (en) | 2015-10-29 |
| US20110190381A1 (en) | 2011-08-04 |
| US20060223773A1 (en) | 2006-10-05 |
| BRPI0609206A2 (pt) | 2010-03-02 |
| JP2008533050A (ja) | 2008-08-21 |
| KR20080018858A (ko) | 2008-02-28 |
| US7947660B2 (en) | 2011-05-24 |
| US9040494B2 (en) | 2015-05-26 |
| US20120178795A1 (en) | 2012-07-12 |
| CA2598234A1 (en) | 2006-09-21 |
| US9550994B2 (en) | 2017-01-24 |
| JP2012193197A (ja) | 2012-10-11 |
| AU2006223131A1 (en) | 2006-09-21 |
| EP1856259A1 (en) | 2007-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007010608A (es) | Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma. | |
| TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
| IL182218A0 (en) | Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity | |
| IL258880A (en) | Diarylhydantoin compounds | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| TW200731979A (en) | RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders | |
| TW200605886A (en) | Indazoles useful in treating cardiovascular diseases | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| TW200626721A (en) | RNAi inhibition of CTGF for treatment of ocular disorders | |
| SG151303A1 (en) | New compounds for the inhibition of angiogenesis and use thereof | |
| NZ590550A (en) | Inhibitors of Apoptosis (IAP) for treating cancer | |
| EA201100874A1 (ru) | Соединения для лечения рака | |
| DE602005007623D1 (de) | Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine | |
| TW200639252A (en) | RNAi-mediated inhibition of ocular hypertension targets | |
| UA85559C2 (en) | Aminobenzophenone compounds | |
| TW200731980A (en) | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis | |
| TW200510333A (en) | Benzimidazole compounds | |
| ATE534633T1 (de) | Indazolderivate zur behandlung von hsp90- induzierten krankheiten | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
| DE60328603D1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| EA200870093A1 (ru) | Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |